VRCA logo

Verrica Pharmaceuticals Inc. Common Stock


VRCA: Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its lead product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a highly contagious and primarily pediatric viral skin disease, and common warts.


Show VRCA Financials

Consumer Interest
SEC Filings

Recent trades of VRCA by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by VRCA's directors and management

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Ampule crush tool Apr. 11, 2023
  • Patent Title: Quantification and preparation of pharmaceutical grade cantharidin Nov. 09, 2021
  • Patent Title: Treatment of cutaneous disorders Oct. 19, 2021
  • Patent Title: Compositions, methods and systems for the treatment of cutaneous disorders Jul. 06, 2021
  • Patent Title: Applicator Oct. 27, 2020
  • Patent Title: Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives Aug. 18, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of VRCA in WallStreetBets Daily Discussion


Recent insights relating to VRCA

CNBC Recommendations

Recent picks made for VRCA stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in VRCA

Corporate Flights

Flights by private jets registered to VRCA